A Phase 3, Double-blind, Placebo-Controlled, Randomized Clinical Trial, Assessing Safety and Efficacy of MF101 for Hot Flashes and Menopausal Symptoms in Postmenopausal Women.

Trial Profile

A Phase 3, Double-blind, Placebo-Controlled, Randomized Clinical Trial, Assessing Safety and Efficacy of MF101 for Hot Flashes and Menopausal Symptoms in Postmenopausal Women.

Suspended
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs MF 101 (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms HERBA
  • Most Recent Events

    • 10 Apr 2012 Status changed from recruiting to suspended due to inadequate funding. A total of 280 patients have been enrolled
    • 28 Mar 2012 The independent Data Safety Monitoring Board recommended that the trial continue unchanged, according to a Bionovo media release.
    • 16 Nov 2011 The first patient has been enrolled, according to a Bionovo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top